Zai Lab Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Product Revenue: Declined 6% year-over-year to $99.6 million, primarily due to lower sales of ZEJULA.

Loss from Operations: Increased by 23% to $69.4 million.

R&D Expenses: Rose 8% year-over-year, driven by increased clinical trial costs.

Cash Position: Ended the quarter with $761.3 million.

Commercial Profitability: The regional business remains profitable, with expectations for sequential revenue growth over the next nine months.

2Strategic Updates and Business Highlights

Pipeline Development: Zai Lab is advancing its R&D capabilities, with a focus on AI integration to enhance drug discovery and clinical trial efficiency.

Zoci: New data presented at AACR shows strong efficacy in small cell lung cancer, with a Phase III study (DLLEVATE) on track for completion in H1 2027. Collaborations with Amgen and Boehringer Ingelheim are underway to explore Zoci in combination therapies.

New Assets: ZL-1503 for atopic dermatitis is in Phase I/Ib studies, and ZL-6201 (LRRC15 ADC) is already in the clinic.

Commercial Initiatives: Strengthening commercial capabilities with the addition of Dr. Yizhe Wang as an operating partner.

3Forward Guidance and Outlook

Revenue Expectations: Anticipate total product revenue to improve sequentially over the next nine months, but expect continued short-term pressure in 2026, with a return to growth projected for 2027.

Regulatory Milestones: Expect to submit the first global BLA for Zoci to the FDA in late 2027.

4Bad News, Challenges, or Points of Concern

ZEJULA Sales Decline: Performance impacted by shifts in hospital utilization and increased competition in the PARP inhibitor class.

Pricing Pressure: VYVGART faced a 12% price discount due to NRDL renewal, which could affect margins.

Supply Constraints: XACDURO's growth is limited by supply issues, expected to persist through the year.

5Notable Q&A Insights

Zoci Collaborations: The combination with T-cell engagers aims to enhance treatment efficacy in small cell lung cancer, with ongoing studies exploring various dosing regimens.

Market Dynamics for VYVGART: Despite new competition, the overall market for gMG biologics remains underpenetrated, providing opportunities for growth.

ZL-1503 Differentiation: The drug aims to provide extended dosing intervals and rapid relief from symptoms, with plans for a Phase II trial following promising Phase I data. Overall, Zai Lab is navigating a challenging market landscape while advancing its clinical pipeline and preparing for future growth, despite some near-term revenue pressures and competitive challenges.